ArticleFrontiers in immunology2024

The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.

Yingfu Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.